Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes

Wilhelm-Benartzi, Charlotte S ; Miller, Sarah E ; Bruggraber, Sylvaine ; Picton, Diane ; Wilson, Mark ; Gatley, Katrina ; Chhabra, Anita ; Marcovecchio, M Loredana ; Hendriks, A Emile J ; Morobé, Hilde ; Chmura, Piotr Jaroslaw ; Bond, Simon ; Aschemeier-Fuchs, Bärbel ; Knip, Mikael ; Tree, Timothy ; Overbergh, Lut ; Pall, Jaivier ; Arnaud, Olivier ; Haller, Michael J ; Nitsche, Almut ; Schulte, Anke M ; Mathieu, Chantal ; Mander, Adrian ; Dunger, David

BMJ open, 2021-12, Vol.11 (12), p.e053669-e053669 [Periódico revisado por pares]

England: British Medical Journal Publishing Group

Texto completo disponível